Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

David James PINATO; Daniela FERRANTE; J. Aguilar-Company; M. Bower; R. Salazar; O. Mirallas; A. Sureda; A. Bertuzzi; J. Brunet; M. Lambertini; C. Maluquer; P. Pedrazzoli; F. Biello; A. J. X. Lee; C. C. T. Sng; R. Linan; S. Rossi; M. C. Carmona-Garcia; R. Sharkey; S. Eremiev; G. Rizzo; H. D. Bain; T. Yu; C. A. Cruz; M. Perachino; N. Saoudi-Gonzalez; R. Fort-Culillas; K. Doonga; L. Fox; E. Roldan; F. Zoratto; Gianluca GAIDANO; I. Ruiz-Camps; R. Bruna; A. Patriarca; M. Shawe-Taylor; V. Fusco; C. Martinez-Vila; R. Berardi; M. Filetti; F. Mazzoni; A. Santoro; S. Delfanti; A. Parisi; P. Queirolo; A. Aujayeb; L. Rimassa; A. Prat; J. Tabernero; Alessandra Gennari; A. Cortellini; J. S. Evans; J. Swallow; G. Hanbury; C. Chung; M. Patel; G. Dettorre; D. Ottaviani; A. Chowdhury; C. C. Sng; A. Sinclair; L. Cooper; L. Rogers; K. Belessiotis; C. Murphy; S. Bawany; S. Khalique; R. Andaleeb; Pria A. Dalla; T. Newsom-Davis; S. Dolly; A. Sita-Lumsde; E. Apthorp; E. Jones; Hemelrijck M. Van; C. Moss; B. Russell; N. Diamantis; U. Mukherjee; S. Townsend; A. Jackson; A. Loizidou; M. Piccart; R. Reyes; E. Segui; J. Marco-Hernandez; M. Viladot; Illescas D. Garcia; N. Saoudi; Garcia M. C. Carmona; R. Fort-Culillas; N. Harbeck; R. Wuerstlein; F. Henze; S. Mahner; R. Mesia; E. Felip; A. Plaja; M. Cucurull; F. D'Avanzo; Lorenza Scotti; M. Krengly; A. Marrari; F. Grosso; A. Maconi; M. Betti; B. Vincenzi; G. Tonini; A. Zambelli; C. Tondini; V. Fotia; L. Chiudinelli; M. Franchi; M. Libertini; R. Bertulli; S. Provenzano; D. Generali; S. Grisanti; A. Baggi; V. Tovazzi; C. Ficorella; G. Porzio; M. Saponara; R. Giusti; M. Tucci; L. Cantini; F. Paoloni; A. Guida; S. Bracarda; M. Iglesias; de Torre A. Sanchez; F. Pommeret; E. Colomba

doi:10.1016/j.ejca.2022.04.036

Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

David James PINATO, Daniela FERRANTE, J. Aguilar-Company, M. Bower, R. Salazar, O. Mirallas, A. Sureda, A. Bertuzzi, J. Brunet, M. Lambertini, C. Maluquer, P. Pedrazzoli, F. Biello, A. J. X. Lee, C. C. T. Sng, R. Linan, S. Rossi, M. C. Carmona-Garcia, R. Sharkey, S. EremievG. Rizzo, H. D. Bain, T. Yu, C. A. Cruz, M. Perachino, N. Saoudi-Gonzalez, R. Fort-Culillas, K. Doonga, L. Fox, E. Roldan, F. Zoratto, Gianluca GAIDANO, I. Ruiz-Camps, R. Bruna, A. Patriarca, M. Shawe-Taylor, V. Fusco, C. Martinez-Vila, R. Berardi, M. Filetti, F. Mazzoni, A. Santoro, S. Delfanti, A. Parisi, P. Queirolo, A. Aujayeb, L. Rimassa, A. Prat, J. Tabernero, Alessandra Gennari, A. Cortellini, J. S. Evans, J. Swallow, G. Hanbury, C. Chung, M. Patel, G. Dettorre, D. Ottaviani, A. Chowdhury, C. C. Sng, A. Sinclair, L. Cooper, L. Rogers, K. Belessiotis, C. Murphy, S. Bawany, S. Khalique, R. Andaleeb, Pria A. Dalla, T. Newsom-Davis, S. Dolly, A. Sita-Lumsde, E. Apthorp, E. Jones, Hemelrijck M. Van, C. Moss, B. Russell, N. Diamantis, U. Mukherjee, S. Townsend, A. Jackson, A. Loizidou, M. Piccart, R. Reyes, E. Segui, J. Marco-Hernandez, M. Viladot, Illescas D. Garcia, N. Saoudi, Garcia M. C. Carmona, R. Fort-Culillas, N. Harbeck, R. Wuerstlein, F. Henze, S. Mahner, R. Mesia, E. Felip, A. Plaja, M. Cucurull, F. D'Avanzo, Lorenza Scotti, M. Krengly, A. Marrari, F. Grosso, A. Maconi, M. Betti, B. Vincenzi, G. Tonini, A. Zambelli, C. Tondini, V. Fotia, L. Chiudinelli, M. Franchi, M. Libertini, R. Bertulli, S. Provenzano, D. Generali, S. Grisanti, A. Baggi, V. Tovazzi, C. Ficorella, G. Porzio, M. Saponara, R. Giusti, M. Tucci, L. Cantini, F. Paoloni, A. Guida, S. Bracarda, M. Iglesias, de Torre A. Sanchez, F. Pommeret, E. Colomba

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Background: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined. Methods: Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients. Results: 2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320). Conclusions: This analysis provides initial evidence in support of the beneficial effect of SARS-CoV-2 vaccines against morbidity and mortality from COVID-19 in patients with cancer.

Lingua originale	Inglese
pagine (da-a)	64-74
Numero di pagine	11
Rivista	European Journal of Cancer
Volume	171
DOI	https://doi.org/10.1016/j.ejca.2022.04.036
Stato di pubblicazione	Pubblicato - 2022

Keywords

Cancer
Clinical efficacy
COVID-19
Prevention
SARS-CoV-2
Vaccines

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.ejca.2022.04.036

https://hdl.handle.net/11579/159463

Altri file e collegamenti

handle

Cita questo

PINATO, D. J., FERRANTE, D., Aguilar-Company, J., Bower, M., Salazar, R., Mirallas, O., Sureda, A., Bertuzzi, A., Brunet, J., Lambertini, M., Maluquer, C., Pedrazzoli, P., Biello, F., Lee, A. J. X., Sng, C. C. T., Linan, R., Rossi, S., Carmona-Garcia, M. C., Sharkey, R., ... Colomba, E. (2022). Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. European Journal of Cancer, 171, 64-74. https://doi.org/10.1016/j.ejca.2022.04.036

@article{6e7e0a54e8434430a97f29f4212abbf6,

title = "Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer",

abstract = "Background: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined. Methods: Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients. Results: 2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320). Conclusions: This analysis provides initial evidence in support of the beneficial effect of SARS-CoV-2 vaccines against morbidity and mortality from COVID-19 in patients with cancer.",

keywords = "Cancer, Clinical efficacy, COVID-19, Prevention, SARS-CoV-2, Vaccines, Cancer, Clinical efficacy, COVID-19, Prevention, SARS-CoV-2, Vaccines",

author = "PINATO, {David James} and Daniela FERRANTE and J. Aguilar-Company and M. Bower and R. Salazar and O. Mirallas and A. Sureda and A. Bertuzzi and J. Brunet and M. Lambertini and C. Maluquer and P. Pedrazzoli and F. Biello and Lee, {A. J. X.} and Sng, {C. C. T.} and R. Linan and S. Rossi and Carmona-Garcia, {M. C.} and R. Sharkey and S. Eremiev and G. Rizzo and Bain, {H. D.} and T. Yu and Cruz, {C. A.} and M. Perachino and N. Saoudi-Gonzalez and R. Fort-Culillas and K. Doonga and L. Fox and E. Roldan and F. Zoratto and Gianluca GAIDANO and I. Ruiz-Camps and R. Bruna and A. Patriarca and M. Shawe-Taylor and V. Fusco and C. Martinez-Vila and R. Berardi and M. Filetti and F. Mazzoni and A. Santoro and S. Delfanti and A. Parisi and P. Queirolo and A. Aujayeb and L. Rimassa and A. Prat and J. Tabernero and Alessandra Gennari and A. Cortellini and Evans, {J. S.} and J. Swallow and G. Hanbury and C. Chung and M. Patel and G. Dettorre and D. Ottaviani and A. Chowdhury and Sng, {C. C.} and A. Sinclair and L. Cooper and L. Rogers and K. Belessiotis and C. Murphy and S. Bawany and S. Khalique and R. Andaleeb and Dalla, {Pria A.} and T. Newsom-Davis and S. Dolly and A. Sita-Lumsde and E. Apthorp and E. Jones and Van, {Hemelrijck M.} and C. Moss and B. Russell and N. Diamantis and U. Mukherjee and S. Townsend and A. Jackson and A. Loizidou and M. Piccart and R. Reyes and E. Segui and J. Marco-Hernandez and M. Viladot and Garcia, {Illescas D.} and N. Saoudi and Carmona, {Garcia M. C.} and R. Fort-Culillas and N. Harbeck and R. Wuerstlein and F. Henze and S. Mahner and R. Mesia and E. Felip and A. Plaja and M. Cucurull and F. D'Avanzo and Lorenza Scotti and M. Krengly and A. Marrari and F. Grosso and A. Maconi and M. Betti and B. Vincenzi and G. Tonini and A. Zambelli and C. Tondini and V. Fotia and L. Chiudinelli and M. Franchi and M. Libertini and R. Bertulli and S. Provenzano and D. Generali and S. Grisanti and A. Baggi and V. Tovazzi and C. Ficorella and G. Porzio and M. Saponara and R. Giusti and M. Tucci and L. Cantini and F. Paoloni and A. Guida and S. Bracarda and M. Iglesias and Sanchez, {de Torre A.} and F. Pommeret and E. Colomba",

year = "2022",

doi = "10.1016/j.ejca.2022.04.036",

language = "English",

volume = "171",

pages = "64--74",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

PINATO, DJ , FERRANTE, D, Aguilar-Company, J, Bower, M, Salazar, R, Mirallas, O, Sureda, A, Bertuzzi, A, Brunet, J, Lambertini, M, Maluquer, C, Pedrazzoli, P, Biello, F, Lee, AJX, Sng, CCT, Linan, R, Rossi, S, Carmona-Garcia, MC, Sharkey, R, Eremiev, S, Rizzo, G, Bain, HD, Yu, T, Cruz, CA, Perachino, M, Saoudi-Gonzalez, N, Fort-Culillas, R, Doonga, K, Fox, L, Roldan, E, Zoratto, F, GAIDANO, G, Ruiz-Camps, I, Bruna, R, Patriarca, A, Shawe-Taylor, M, Fusco, V, Martinez-Vila, C, Berardi, R, Filetti, M, Mazzoni, F, Santoro, A, Delfanti, S, Parisi, A, Queirolo, P, Aujayeb, A, Rimassa, L, Prat, A, Tabernero, J, Gennari, A, Cortellini, A, Evans, JS, Swallow, J, Hanbury, G, Chung, C, Patel, M, Dettorre, G, Ottaviani, D, Chowdhury, A, Sng, CC, Sinclair, A, Cooper, L, Rogers, L, Belessiotis, K, Murphy, C, Bawany, S, Khalique, S, Andaleeb, R, Dalla, PA, Newsom-Davis, T, Dolly, S, Sita-Lumsde, A, Apthorp, E, Jones, E, Van, HM, Moss, C, Russell, B, Diamantis, N, Mukherjee, U, Townsend, S, Jackson, A, Loizidou, A, Piccart, M, Reyes, R, Segui, E, Marco-Hernandez, J, Viladot, M, Garcia, ID, Saoudi, N, Carmona, GMC, Fort-Culillas, R, Harbeck, N, Wuerstlein, R, Henze, F, Mahner, S, Mesia, R, Felip, E, Plaja, A, Cucurull, M, D'Avanzo, F, Scotti, L, Krengly, M, Marrari, A, Grosso, F, Maconi, A, Betti, M, Vincenzi, B, Tonini, G, Zambelli, A, Tondini, C, Fotia, V, Chiudinelli, L, Franchi, M, Libertini, M, Bertulli, R, Provenzano, S, Generali, D, Grisanti, S, Baggi, A, Tovazzi, V, Ficorella, C, Porzio, G, Saponara, M, Giusti, R, Tucci, M, Cantini, L, Paoloni, F, Guida, A, Bracarda, S, Iglesias, M, Sanchez, DTA, Pommeret, F & Colomba, E 2022, 'Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer', European Journal of Cancer, vol. 171, pagg. 64-74. https://doi.org/10.1016/j.ejca.2022.04.036

TY - JOUR

T1 - Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

AU - PINATO, David James

AU - FERRANTE, Daniela

AU - Aguilar-Company, J.

AU - Bower, M.

AU - Salazar, R.

AU - Mirallas, O.

AU - Sureda, A.

AU - Bertuzzi, A.

AU - Brunet, J.

AU - Lambertini, M.

AU - Maluquer, C.

AU - Pedrazzoli, P.

AU - Biello, F.

AU - Lee, A. J. X.

AU - Sng, C. C. T.

AU - Linan, R.

AU - Rossi, S.

AU - Carmona-Garcia, M. C.

AU - Sharkey, R.

AU - Eremiev, S.

AU - Rizzo, G.

AU - Bain, H. D.

AU - Yu, T.

AU - Cruz, C. A.

AU - Perachino, M.

AU - Saoudi-Gonzalez, N.

AU - Fort-Culillas, R.

AU - Doonga, K.

AU - Fox, L.

AU - Roldan, E.

AU - Zoratto, F.

AU - GAIDANO, Gianluca

AU - Ruiz-Camps, I.

AU - Bruna, R.

AU - Patriarca, A.

AU - Shawe-Taylor, M.

AU - Fusco, V.

AU - Martinez-Vila, C.

AU - Berardi, R.

AU - Filetti, M.

AU - Mazzoni, F.

AU - Santoro, A.

AU - Delfanti, S.

AU - Parisi, A.

AU - Queirolo, P.

AU - Aujayeb, A.

AU - Rimassa, L.

AU - Prat, A.

AU - Tabernero, J.

AU - Gennari, Alessandra

AU - Cortellini, A.

AU - Evans, J. S.

AU - Swallow, J.

AU - Hanbury, G.

AU - Chung, C.

AU - Patel, M.

AU - Dettorre, G.

AU - Ottaviani, D.

AU - Chowdhury, A.

AU - Sng, C. C.

AU - Sinclair, A.

AU - Cooper, L.

AU - Rogers, L.

AU - Belessiotis, K.

AU - Murphy, C.

AU - Bawany, S.

AU - Khalique, S.

AU - Andaleeb, R.

AU - Dalla, Pria A.

AU - Newsom-Davis, T.

AU - Dolly, S.

AU - Sita-Lumsde, A.

AU - Apthorp, E.

AU - Jones, E.

AU - Van, Hemelrijck M.

AU - Moss, C.

AU - Russell, B.

AU - Diamantis, N.

AU - Mukherjee, U.

AU - Townsend, S.

AU - Jackson, A.

AU - Loizidou, A.

AU - Piccart, M.

AU - Reyes, R.

AU - Segui, E.

AU - Marco-Hernandez, J.

AU - Viladot, M.

AU - Garcia, Illescas D.

AU - Saoudi, N.

AU - Carmona, Garcia M. C.

AU - Fort-Culillas, R.

AU - Harbeck, N.

AU - Wuerstlein, R.

AU - Henze, F.

AU - Mahner, S.

AU - Mesia, R.

AU - Felip, E.

AU - Plaja, A.

AU - Cucurull, M.

AU - D'Avanzo, F.

AU - Scotti, Lorenza

AU - Krengly, M.

AU - Marrari, A.

AU - Grosso, F.

AU - Maconi, A.

AU - Betti, M.

AU - Vincenzi, B.

AU - Tonini, G.

AU - Zambelli, A.

AU - Tondini, C.

AU - Fotia, V.

AU - Chiudinelli, L.

AU - Franchi, M.

AU - Libertini, M.

AU - Bertulli, R.

AU - Provenzano, S.

AU - Generali, D.

AU - Grisanti, S.

AU - Baggi, A.

AU - Tovazzi, V.

AU - Ficorella, C.

AU - Porzio, G.

AU - Saponara, M.

AU - Giusti, R.

AU - Tucci, M.

AU - Cantini, L.

AU - Paoloni, F.

AU - Guida, A.

AU - Bracarda, S.

AU - Iglesias, M.

AU - Sanchez, de Torre A.

AU - Pommeret, F.

AU - Colomba, E.

PY - 2022

Y1 - 2022

N2 - Background: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined. Methods: Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients. Results: 2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320). Conclusions: This analysis provides initial evidence in support of the beneficial effect of SARS-CoV-2 vaccines against morbidity and mortality from COVID-19 in patients with cancer.

AB - Background: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined. Methods: Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients. Results: 2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320). Conclusions: This analysis provides initial evidence in support of the beneficial effect of SARS-CoV-2 vaccines against morbidity and mortality from COVID-19 in patients with cancer.

KW - Cancer

KW - Clinical efficacy

KW - COVID-19

KW - Prevention

KW - SARS-CoV-2

KW - Vaccines

KW - Cancer

KW - Clinical efficacy

KW - COVID-19

KW - Prevention

KW - SARS-CoV-2

KW - Vaccines

UR - https://iris.uniupo.it/handle/11579/159463

U2 - 10.1016/j.ejca.2022.04.036

DO - 10.1016/j.ejca.2022.04.036

M3 - Article

SN - 0959-8049

VL - 171

SP - 64

EP - 74

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo